<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="160185">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01013350</url>
  </required_header>
  <id_info>
    <org_study_id>EMR700568-012</org_study_id>
    <secondary_id>2009-017978-21</secondary_id>
    <nct_id>NCT01013350</nct_id>
  </id_info>
  <brief_title>Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials</brief_title>
  <acronym>PREMIERE</acronym>
  <official_title>Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients who Have
      Participated in Cladribine Clinical Trials
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with serious adverse drug reactions (SADRs)</measure>
    <time_frame>Up to the end of the registry, which is planned for 2018, or 8 years after the subject's first enrolment into a cladribine clinical trial, whichever occurs first</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to resolution of lymphopenia, among registry participants with persistent lymphopenia</measure>
    <time_frame>Up to the end of the registry, which is planned for 2018, or 8 years after the subject's first enrolment into a cladribine clinical trial, whichever occurs first</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with all Adverse Events (AEs) in the &quot;Blood and Lymphatic System Disorders&quot; System Organ Class (SOC) and in the &quot;Neoplasms Benign, Malignant, and Unspecified&quot; SOC</measure>
    <time_frame>Up to the end of the registry, which is planned for 2018, or 8 years after the subject's first enrolment into a cladribine clinical trial, whichever occurs first</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcomes</measure>
    <time_frame>Up to the end of the registry, which is planned for 2018, or 8 years after the subject's first enrolment into a cladribine clinical trial, whichever occurs first</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1190</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cladribine</arm_group_label>
    <description>This is an observational study. Subjects who had already participated in the cladribine clinical trials will be observed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>This is an observational study. Subjects who had already participated in the cladribine clinical trials will be observed.</description>
    <arm_group_label>Cladribine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with Multiple Sclerosis and had already participated in Sponsor oral cladribine
        clinical development trials
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior enrollment into selected oral cladribine clinical trials as of randomization to
             either study drug or placebo, once participation in the clinical trial has ended

          -  Written informed consent was given

        Exclusion Criteria:

          -  Subjects who cannot be reached by telephone

          -  Subjects unable to answer the registry questionnaires and who do not have a next of
             kin or caregiver able to answer the registry questionnaires

          -  Subjects who - either during the lag interval or subsequently - enter an
             interventional study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono Inc., an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Outcome Sciences, Inc</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Outcome Sciences, Inc Sciences, Inc</last_name>
      <phone>617-674-8421</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 14, 2016</lastchanged_date>
  <firstreceived_date>November 11, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Cladribine</keyword>
  <keyword>PREMIERE</keyword>
  <keyword>Observational study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
